$CRMD
CorMedix Inc. Stock $crmd

$crmd Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023024310 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$29.70K	$65.41K
YoY Change		-47.34%	-65.74%
Cost Of Revenue		$410.00	$3.734K
YoY Change		-99.15%	-97.49%
Gross Profit		$29.29K	$61.67K
YoY Change		249.11%	46.84%
Gross Profit Margin		98.62%	94.29%
Selling, General & Admin	$7.610M	$5.575M	$20.01M
YoY Change	60.17%	22.45%	22.39%
% of Gross Profit		19034.82%	32438.46%
Research & Development	$3.408M	$2.843M	$10.68M
YoY Change	48.96%	-12.12%	-18.68%
% of Gross Profit		9707.14%	17316.13%
Depreciation & Amortization	$16.86K	$22.52K	$84.62K
YoY Change	-16.73%	12.32%	36.72%
% of Gross Profit		76.89%	137.2%
Operating Expenses	$11.02M	$8.419M	$30.69M
YoY Change	56.53%	8.09%	4.09%
Operating Profit	-$11.02M	-$8.389M	-$30.62M
YoY Change	56.66%	7.83%	4.03%
Interest Expense	$8.776K	$180.3K	$26.52K
YoY Change	-579.56%	-1728.46%	-216.19%
% of Operating Profit
Other Income/Expense, Net	$450.0K		$336.6K
YoY Change	-24647.35%		-1574.77%
Pretax Income	-$10.57M	-$8.209M	-$30.29M
YoY Change	50.23%	5.36%	2.81%
Income Tax		$0.00	-$585.6K
% Of Pretax Income
Net Earnings	-$10.57M	-$8.209M	-$29.70M
YoY Change	50.23%	5.36%	5.29%
Net Earnings / Revenue		-27639.56%	-45409.9%
Basic Earnings Per Share	-$0.24		-$0.74
Diluted Earnings Per Share	-$0.24	-$0.20	-$0.74
COMMON SHARES
Basic Shares Outstanding	44.50M shares	41.28M shares	40.27M shares
Diluted Shares Outstanding	44.09M shares		40.27M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$55.60M	$58.79M	$58.79M
YoY Change	-9.87%	-10.19%	-10.19%
Cash & Equivalents	$25.27M	$43.15M	$43.15M
Short-Term Investments	$30.33M	$15.64M	$15.64M
Other Short-Term Assets	$1.181M	$758.8K	$758.8K
YoY Change	45.71%	-20.47%	-20.47%
Inventory			$0.00
Prepaid Expenses	$2.910K	$11.02K
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$56.78M	$59.55M	$59.55M
YoY Change	-9.15%	-10.41%	-10.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.608M	$1.610M	$2.385M
YoY Change	-30.95%	9.14%	0.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$102.4K	$102.3K	$102.3K
YoY Change	0.04%	0.01%	0.01%
Total Long-Term Assets	$2.452M	$2.487M	$2.487M
YoY Change	0.9%	0.42%	0.42%
TOTAL ASSETS
Total Short-Term Assets	$56.78M	$59.55M	$59.55M
Total Long-Term Assets	$2.452M	$2.487M	$2.487M
Total Assets	$59.23M	$62.04M	$62.04M
YoY Change	-8.78%	-10.02%	-10.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.447M	$2.202M	$2.202M
YoY Change	-16.86%	-0.34%	-0.33%
Accrued Expenses	$3.089M	$3.974M	$4.109M
YoY Change	20.95%	31.84%	31.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.675M	$6.311M	$6.311M
YoY Change	8.85%	18.07%	18.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$631.4K	$667.6K	$667.6K
YoY Change	-18.0%	-16.8%	-16.8%
Total Long-Term Liabilities	$631.4K	$667.6K	$667.6K
YoY Change	-18.0%	-16.8%	-16.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.675M	$6.311M	$6.311M
Total Long-Term Liabilities	$631.4K	$667.6K	$667.6K
Total Liabilities	$5.306M	$6.979M	$6.979M
YoY Change	4.77%	13.52%	13.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$285.9M	-$275.4M
YoY Change		12.09%
Common Stock	$44.50K	$42.82K
YoY Change		12.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.93M	$55.06M	$55.06M
YoY Change
Total Liabilities & Shareholders Equity	$59.23M	$62.04M	$62.04M
YoY Change	-8.78%	-10.02%	-10.02%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$10.57M	-$8.209M	-$29.70M
YoY Change	50.23%	5.36%	5.29%
Depreciation, Depletion And Amortization	$16.86K	$22.52K	$84.62K
YoY Change	-16.73%	12.32%	36.72%
Cash From Operating Activities	-$10.39M	-$6.155M	-$24.36M
YoY Change	54.11%	4.86%	15.13%
INVESTING ACTIVITIES
Capital Expenditures	$14.77K	$128.8K	$219.4K
YoY Change	-441.81%	-120.48%	-115.39%
Acquisitions
YoY Change
Other Investing Activities	-$14.67M	$126.9K	-$3.490M
YoY Change	250.73%	-101.95%	-54.73%
Cash From Investing Activities	-$14.69M	-$1.860K	-$3.709M
YoY Change	250.72%	-99.97%	-59.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$17.77M
YoY Change			-57.45%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.200M	6.046M	$17.90M
YoY Change	139.68%		-57.14%
NET CHANGE
Cash From Operating Activities	-$10.39M	-6.155M	-$24.36M
Cash From Investing Activities	-$14.69M	-1.860K	-$3.709M
Cash From Financing Activities	$7.200M	6.046M	$17.90M
Net Change In Cash	-$17.88M	-111.1K	-$10.18M
YoY Change	125.51%	-99.15%	-188.74%
FREE CASH FLOW
Cash From Operating Activities	-$10.39M	-$6.155M	-$24.36M
Capital Expenditures	$14.77K	$128.8K	$219.4K
Free Cash Flow	-$10.41M	-$6.284M	-$24.58M
YoY Change	54.43%	19.9%	24.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-34673
CY2022	dei	Entity Registrant Name EntityRegistrantName	CORMEDIX INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5894890
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	300 Connell Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 4200
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Berkeley Heights
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07922
CY2022	dei	City Area Code CityAreaCode	(908)
CY2022	dei	Local Phone Number LocalPhoneNumber	517-9500
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2022	dei	Trading Symbol TradingSymbol	CRMD
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	163900000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44499788	shares
CY2022	dei	Auditor Name AuditorName	Marcum LLP
CY2022	dei	Auditor Firm AuditorFirmId	711
CY2022	dei	Auditor Location AuditorLocation	Marlton, NJ
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43148323	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53317405	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	124102	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	131567	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	15644062	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	12149003	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	45368	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	3008	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	11016	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	51993	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	623672	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	770485	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	59551175	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	66468829	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1609679	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1474937	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102320	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	102305	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	775085	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899505	usd
CY2022Q4	us-gaap	Assets Assets	62038259	usd
CY2021Q4	us-gaap	Assets Assets	68945576	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2202149	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2209552	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3973941	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3014156	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	134801	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	121368	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6310891	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5345076	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	667632	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	802433	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6978523	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6147509	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	181622	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	182	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	160000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42815196	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42815196	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38086437	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38086437	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42815	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	38086	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	82743	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	87130	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	330294782	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	308331750	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275360786	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245659081	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62038259	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68945576	usd
CY2022	us-gaap	Revenues Revenues	65408	usd
CY2021	us-gaap	Revenues Revenues	190936	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3734	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	148938	usd
CY2022	us-gaap	Gross Profit GrossProfit	61674	usd
CY2021	us-gaap	Gross Profit GrossProfit	41998	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10679549	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13132982	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20006093	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16346601	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	30685642	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	29479583	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-30623968	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-29437585	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	326016	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	14403	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	37145	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-21287	usd
CY2022	us-gaap	Interest Expense InterestExpense	26515	usd
CY2021	us-gaap	Interest Expense InterestExpense	15943	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	336646	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22827	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30287322	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29460412	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-585617	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250186	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29701705	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28210226	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	-5055	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Transition Asset Obligation Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax	4655	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9442	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-10221	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4387	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-14876	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29706092	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28225102	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40274273	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37666081	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	44223012	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	41455630	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	164886	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	137035	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	5042606	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-14876	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28210226	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	62798067	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17769616	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	128625	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	4069520	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-4387	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29701705	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	55059736	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-29701705	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-28210226	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4069520	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5042606	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	124420	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	115130	usd
CY2022	us-gaap	Depreciation Depreciation	84618	usd
CY2021	us-gaap	Depreciation Depreciation	61890	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-42143	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	44080	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3008	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-145456	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-187235	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-666628	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6566	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1082129	usd
CY2022	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	-961963	usd
CY2021	crmd	Increase Decrease In Accrued Expenses IncreaseDecreaseInAccruedExpenses	-94279	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-121368	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-109035	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24356732	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21155223	usd
CY2022	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	31140004	usd
CY2021	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	15289586	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	27650000	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	7580000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	219360	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1425329	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3709364	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9134915	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17769616	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	41455630	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	128625	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	164886	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	137035	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17898241	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41757551	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-8677	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-12919	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10176532	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11454494	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53551277	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42096783	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43374745	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53551277	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	26516	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	15943	usd
CY2021	crmd	Conversion Of Series G Preferred Stock To Common Stock ConversionOfSeriesGPreferredStockToCommonStock	10	usd
CY2021	crmd	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	50	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	5055	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4655	usd
CY2021	crmd	Deposit On Equipment Reclassified From Prepaid Expenses And Current Assets To Property And Equipment DepositOnEquipmentReclassifiedFromPrepaidExpensesAndCurrentAssetsToPropertyAndEquipment	501821	usd
CY2022	crmd	At The Market Issuance Sales Agreement AtTheMarketIssuanceSalesAgreement	50000000	usd
CY2022	crmd	Available For The Issuance Of Equity AvailableForTheIssuanceOfEquity	150000000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Use of Estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> </p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43148323	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53317405	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	226422	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	233872	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	43374745	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	53551277	usd
CY2022Q4	crmd	Amortized Cost AmortizedCost	22956564	usd
CY2022Q4	crmd	Gross Unrealized Losses GrossUnrealizedLosses	4140	usd
CY2022Q4	crmd	Gross Unrealized Gains GrossUnrealizedGains	3537	usd
CY2022Q4	crmd	Fair Value FairValue	22955961	usd
CY2021Q4	crmd	Amortized Cost AmortizedCost	22617515	usd
CY2021Q4	crmd	Gross Unrealized Losses GrossUnrealizedLosses	5751	usd
CY2021Q4	crmd	Gross Unrealized Gains GrossUnrealizedGains	93	usd
CY2021Q4	crmd	Fair Value FairValue	22611857	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22955961	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22611857	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	9442	usd
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	10221	usd
CY2021Q4	crmd	Cash Reimbursed CashReimbursed	48000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	124000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	132000	usd
CY2022Q4	crmd	Longterm Restricted Cash LongtermRestrictedCash	102000	usd
CY2021Q4	crmd	Longterm Restricted Cash LongtermRestrictedCash	102000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3008	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1609679	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1474937	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	449787	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	365169	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10110769	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8863517	shares
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4430000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	172000	usd
CY2022	crmd	Reported Revenues ReportedRevenues	65408	usd
CY2021	crmd	Reported Revenues ReportedRevenues	190936	usd
CY2022	crmd	Revenues Attributable From Countries RevenuesAttributableFromCountries	65408	usd
CY2021	crmd	Revenues Attributable From Countries RevenuesAttributableFromCountries	190936	usd
CY2022Q4	us-gaap	Assets Assets	62038259	usd
CY2021Q4	us-gaap	Assets Assets	68945576	usd
CY2022	crmd	Total Assets Located In Countries TotalAssetsLocatedInCountries	61740478	usd
CY2021	crmd	Total Assets Located In Countries TotalAssetsLocatedInCountries	68558413	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	514354	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	311408	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2180581	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2508398	usd
CY2022	crmd	Manufacturing Development Related ManufacturingDevelopmentRelated	1214550	usd
CY2021	crmd	Manufacturing Development Related ManufacturingDevelopmentRelated	99614	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	64456	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	94736	usd
CY2022	crmd	Total Accured Expenses TotalAccuredExpenses	3973941	usd
CY2021	crmd	Total Accured Expenses TotalAccuredExpenses	3014156	usd
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	556069	shares
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Government Grants IncomeTaxExpenseBenefitContinuingOperationsGovernmentGrants	-30287322	usd
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Government Grants IncomeTaxExpenseBenefitContinuingOperationsGovernmentGrants	-29460412	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	47683000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	44085000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1592000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	3717000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	10000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5000	usd
CY2022Q4	crmd	Deferred Tax Assets Capitalized Licensing Fees DeferredTaxAssetsCapitalizedLicensingFees	304000	usd
CY2021Q4	crmd	Deferred Tax Assets Capitalized Licensing Fees DeferredTaxAssetsCapitalizedLicensingFees	449000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5270000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	320000	usd
CY2022Q4	crmd	Capitalization Capitalization	2702000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	28000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-17000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57761000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	52989000	usd
CY2022Q4	crmd	Income Tax Reconciliation Changes In Deferred Tax Assets Valuation Allowances IncomeTaxReconciliationChangesInDeferredTaxAssetsValuationAllowances	57761000	usd
CY2021Q4	crmd	Income Tax Reconciliation Changes In Deferred Tax Assets Valuation Allowances IncomeTaxReconciliationChangesInDeferredTaxAssetsValuationAllowances	52989000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.80	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.043	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.035	pure
CY2022	crmd	Effective Income Tax Rate Reconciliation Adjusted Foreign Nol EffectiveIncomeTaxRateReconciliationAdjustedForeignNOL	-0.002	pure
CY2021	crmd	Effective Income Tax Rate Reconciliation Adjusted Foreign Nol EffectiveIncomeTaxRateReconciliationAdjustedForeignNOL	-0.083	pure
CY2022	crmd	Njnol Adjustment NJNOLAdjustment	0.019	pure
CY2021	crmd	Njnol Adjustment NJNOLAdjustment	0.042	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.008	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.009	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.157	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.153	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.019	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.042	pure
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52989000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4805000	usd
CY2022	crmd	Increase Decrease Charged Credited To Oci IncreaseDecreaseChargedCreditedToOCI	-32000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57762000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48480000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4541000	usd
CY2021	crmd	Increase Decrease Charged Credited To Oci IncreaseDecreaseChargedCreditedToOCI	-32000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52989000	usd
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	586000	usd
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	1250000	usd
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	626000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	626000	usd
CY2020	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	1337000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1337000	usd
CY2020	us-gaap	Reimbursement From Limited Partnership Investment ReimbursementFromLimitedPartnershipInvestment	30000	usd
CY2022	crmd	Cash Reimburse CashReimburse	41000	usd
CY2022	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	124000	usd
CY2022	crmd	Aggregate Deposit Amount AggregateDepositAmount	75000	usd
CY2008Q4	crmd	Amount Of Initial Licensing Fee AmountOfInitialLicensingFee	325000	usd
CY2008Q4	crmd	Shares Of Equity Of Common Stock SharesOfEquityOfCommonStock	7996	shares
CY2022	us-gaap	Stock Issued During Period Shares Period Increase Decrease StockIssuedDuringPeriodSharesPeriodIncreaseDecrease	29109	shares
CY2014	crmd	Number Of Shares Released In Escrow NumberOfSharesReleasedInEscrow	7277	shares
CY2022	crmd	Number Of Share Held In Escrow Of Common Stock NumberOfShareHeldInEscrowOfCommonStock	21832	shares
CY2022	crmd	Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones	3000000	usd
CY2022	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
CY2021	crmd	Balance Of Cash Payments Due Upon Achievement Of Milestones BalanceOfCashPaymentsDueUponAchievementOfMilestones	2500000	usd
CY2021Q3	crmd	Aggregate Amount AggregateAmount	50000000	usd
CY2021Q3	crmd	Commission Percentage Of Gross Proceeds CommissionPercentageOfGrossProceeds	0.03	pure
CY2022Q4	crmd	Available Amount AvailableAmount	31600000	usd
CY2022	crmd	Net Proceed NetProceed	129000	usd
CY2021	crmd	Net Proceed NetProceed	165000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	207469	shares
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.38
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y4M24D
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	181622	shares
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	21291665	usd
CY2021	crmd	Preferred Shares Was Converted Description PreferredSharesWasConvertedDescription	During the year ended December 31, 2021, 50,000 Series C-3 preferred shares were converted into 100,000 shares of the Company’s common stock by an unrelated party and 10,001 Series G preferred shares were converted into 556,069 shares of the Company’s common stock by a related party.
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2022	crmd	Common Stock Percentage CommonStockPercentage	0.0999	pure
CY2022	us-gaap	Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears PreferredStockPerShareAmountsOfPreferredDividendsInArrears	10
CY2022	crmd	Voting Convertible Preferred Stock Description VotingConvertiblePreferredStockDescription	Each share of Series E preferred stock is convertible into 4.3733 shares of our common stock (subject to adjustment as provided in the certificates of designation for the Series E preferred stock) at a per share price of $3.75 at any time at the option of the holder, except that a holder will be prohibited from converting shares of Series E preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 4.99% of the total number of shares of our common stock then issued and outstanding.
CY2022	crmd	Aggregate Principal Amount AggregatePrincipalAmount	10000000	usd
CY2022Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	5000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.9
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.56
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3358131	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.53
CY2022	crmd	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	337075	usd
CY2022	crmd	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross	1627850	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.83
CY2022	crmd	Aggregate Intrinsic Value Grantedin Dollars Per Share AggregateIntrinsicValueGrantedinDollarsPerShare	793792	usd
CY2022	crmd	Shares Underlying Stock Options Expired Canceled SharesUnderlyingStockOptionsExpiredCanceled	-60053	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8
CY2022	crmd	Aggregate Intrinsic Value Expired Canceled AggregateIntrinsicValueExpiredCanceled	4968	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	471559	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.16
CY2022	crmd	Aggregate Intrinsic Value Forfeiteds AggregateIntrinsicValueForfeiteds	12849	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4454369	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1113050	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2638516	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.26
CY2022	crmd	Weighted Average Remaining Contractual Term Years Vested WeightedAverageRemainingContractualTermYearsVested	P5Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	366528	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1815853	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.69
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y10M24D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	746522	usd
CY2021	crmd	Common Stock Cashless Exercise CommonStockCashlessExercise	70269	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	56455	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.25
CY2022	crmd	Weighted Average Remaining Contractual Life Beginning WeightedAverageRemainingContractualLifeBeginning	P0Y7M9D
CY2022	crmd	Number Of Shares Underlying Warrants Exercised NumberOfSharesUnderlyingWarrantsExercised	24500	shares
CY2022	crmd	Weighted Average Exercise Prices Exercised WeightedAverageExercisePricesExercised	5.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	31955	shares
CY2022	crmd	Weighted Average Exercise Price Expired WeightedAverageExercisePriceExpired	5.25
CY2022	crmd	Accounts Receivable From Customers Percentage AccountsReceivableFromCustomersPercentage	0.10	pure
CY2022	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The Company entered into a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey 07922.
CY2020Q3	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	17000	usd
CY2022Q4	crmd	Rental Agreement Expense RentalAgreementExpense	400	eur
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	208000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	209000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	803000	usd
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	924000	usd
CY2022	crmd	Shortterm Leases ShorttermLeases	135000	usd
CY2021	crmd	Shortterm Leases ShorttermLeases	668000	usd
CY2022Q4	crmd	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	775000	usd
CY2021Q4	crmd	Operating Lease Right Of Use Assets OperatingLeaseRightOfUseAssets	900000	usd
CY2022	crmd	Operating Leases OperatingLeases	199000	usd
CY2021	crmd	Operating Leases OperatingLeases	195000	usd
CY2022	crmd	Weighted Average Remaining Description WeightedAverageRemainingDescription	As of December 31, 2022 and 2021, the weighted average remaining lease term were 4.8 years and 5.8 years, respectively and the weighted average discount rate of 9% and 9% at December 31, 2022 and 2021, respectively.
CY2022Q4	crmd	Operating Leases Future Minimum Payment Due In Rolling Year Two OperatingLeasesFutureMinimumPaymentDueInRollingYearTwo	202000	usd
CY2022Q4	crmd	Operating Leases Future Minimum Payment Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentDueInRollingYearThree	205000	usd
CY2022Q4	crmd	Operating Leases Future Minimum Payments Due In Four Year OperatingLeasesFutureMinimumPaymentsDueInFourYear	208000	usd
CY2022Q4	crmd	Operating Leases Future Minimum Payment Due Thereafter OperatingLeasesFutureMinimumPaymentDueThereafter	380000	usd
CY2022Q4	crmd	Future Minimum Lease Payments FutureMinimumLeasePayments	995000	usd
CY2022Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	192000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	803000	usd
CY2022	crmd	Atm Program Descroption ATMProgramDescroption	Through March 30, 2023, the Company sold an aggregate of 1,684,592 shares of its common stock under the ATM program (see Note 9) and realized net proceeds of approximately $7,200,000. As of the filing of this Annual Report on Form 10-K, the Company has $24,200,000 available balance under its ATM program and it has $150,000,000 available under its current shelf registration for the issuance of equity, debt or equity-linked securities.
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37666081	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40274273	shares
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	crmd	Conversion Of Series G Preferred Stock To Common Stock ConversionOfSeriesGPreferredStockToCommonStock		usd
CY2022	crmd	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
CY2022	crmd	Deposit On Equipment Reclassified From Prepaid Expenses And Current Assets To Property And Equipment DepositOnEquipmentReclassifiedFromPrepaidExpensesAndCurrentAssetsToPropertyAndEquipment		usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2021Q4	crmd	Capitalization Capitalization		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	crmd	Shares Underlying Stock Options Exercised SharesUnderlyingStockOptionsExercised		shares
CY2022	crmd	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised
CY2022	crmd	Aggregate Intrinsic Value Exerciseds AggregateIntrinsicValueExerciseds		usd
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	crmd	Weighted Average Remaining Contractual Life Ending WeightedAverageRemainingContractualLifeEnding
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001410098

Files In Submission

Name	View Source	Status
crmd-20221231_pre.xml	Edgar Link	unprocessable
0001213900-23-024310-index-headers.html	Edgar Link	pending
0001213900-23-024310-index.html	Edgar Link	pending
0001213900-23-024310.txt	Edgar Link	pending
0001213900-23-024310-xbrl.zip	Edgar Link	pending
crmd-20221231.xsd	Edgar Link	pending
f10k2022ex10-1_cormedixinc.htm	Edgar Link	pending
f10k2022ex23-1_cormedixinc.htm	Edgar Link	pending
f10k2022ex23-2_cormedixinc.htm	Edgar Link	pending
f10k2022ex31-1_cormedixinc.htm	Edgar Link	pending
f10k2022ex31-2_cormedixinc.htm	Edgar Link	pending
f10k2022ex32-1_cormedixinc.htm	Edgar Link	pending
f10k2022ex32-2_cormedixinc.htm	Edgar Link	pending
f10k2022_cormedixinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
crmd-20221231_cal.xml	Edgar Link	unprocessable
crmd-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_cormedixinc_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
crmd-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRMD
CorMedix Inc. Stock $crmd

2023 Q1 Form 10-K Financial Statement

#000121390023024310 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD CorMedix Inc. Stock $crmd

2023 Q1 Form 10-K Financial Statement

#000121390023024310 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRMD
CorMedix Inc. Stock $crmd